2021
Atrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence
Vrachatis DA, Papathanasiou KA, Kossyvakis C, Giotaki SG, Raisakis K, Iliodromitis KE, Reimers B, Stefanini GG, Cleman M, Sianos G, Lansky A, Deftereos SG, Giannopoulos G. Atrial fibrillation risk in patients suffering from type I diabetes mellitus. A review of clinical and experimental evidence. Diabetes Research And Clinical Practice 2021, 174: 108724. PMID: 33647332, DOI: 10.1016/j.diabres.2021.108724.Peer-Reviewed Original ResearchConceptsDiabetes mellitusAtrial fibrillationType 1 diabetes mellitusIndependent risk factorAtrial fibrillation managementAtrial fibrillation riskAF developmentInsulin deficiencyGlycemic variabilityRisk factorsClinical dataClinical studiesMicrovascular sequelaeAtrial arrhythmogenesisAnimal studiesAtrial myocytesClinical practiceArrhythmia initiationStructural remodelingClinical implicationsT1DMOxidative stressPI3KGlucose transportationMellitus
2013
Clinical implications for diffusion‐weighted MRI brain lesions associated with transcatheter aortic valve replacement
Meller SM, Baumbach A, Brickman AM, Lansky AJ. Clinical implications for diffusion‐weighted MRI brain lesions associated with transcatheter aortic valve replacement. Catheterization And Cardiovascular Interventions 2013, 83: 502-508. PMID: 23460315, DOI: 10.1002/ccd.24904.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementSilent strokeValve replacementCerebral embolic protection devicesDiffusion-weighted magnetic resonance imagingEmbolic protection devicesCerebral protection devicesMRI brain lesionsPotential therapeutic optionQuality of lifeLong-term cognitive consequencesMagnetic resonance imagingNeurological complicationsAortic stenosisImproved survivalNew lesionsEmbolic lesionsTherapeutic optionsBrain lesionsRisk candidatesCognitive declineResonance imagingClinical implicationsLesions
2004
Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction
Costantini CO, Stone GW, Mehran R, Aymong E, Grines CL, Cox DA, Stuckey T, Turco M, Gersh BJ, Tcheng JE, Garcia E, Griffin JJ, Guagliumi G, Leon MB, Lansky AJ. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction. Journal Of The American College Of Cardiology 2004, 44: 305-312. PMID: 15261923, DOI: 10.1016/j.jacc.2004.03.058.Peer-Reviewed Original ResearchConceptsAcute myocardial infarctionIIb/IIIa inhibitorsTissue-level perfusionMyocardial perfusionPrimary angioplastyMyocardial infarctionGlycoprotein IIb/IIIa inhibitionGlycoprotein IIb/IIIa inhibitorsGP IIb/IIIa inhibitorsClinical implicationsIIb/IIIa inhibitionSimilar long-term mortalityLarge-scale prospective studiesMechanical reperfusion strategiesLong-term mortalityMyocardial blush gradeMinority of patientsNormal myocardial perfusionDistinct risk categoriesBlush gradePrimary PCIReperfusion strategyMyocardial reperfusionBalloon angioplastyPrognostic importance
2003
Clinical implications of myocardial perfusion status assessed by myocardial blush after primary angioplasty in acute myocardial infarction: Analysis from the CADILLAC trial
Costantini C, Lansky A, Shirai K, Cristea E, Brestowski C, Slack S, Fahy M, Grines C, Carroll J, Thomas S, Guagliumi G, Rutherford B, Turco M, Mathias D, Leon M, Stone G. Clinical implications of myocardial perfusion status assessed by myocardial blush after primary angioplasty in acute myocardial infarction: Analysis from the CADILLAC trial. Journal Of The American College Of Cardiology 2003, 41: 391-392. DOI: 10.1016/s0735-1097(03)81126-9.Peer-Reviewed Original Research